FDA Adds Vision-Loss Warning to All GLP-1s

If you take a GLP-1, you may have seen the news about vision loss. On November 9, the FDA said it will require every GLP-1 medication to carry a new warning about NAION, a rare eye condition that can cause sudden vision loss in one eye (FDA). That includes Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo.

It's a scary headline, but the condition is rare, and the FDA hasn't said to stop taking these drugs. It does want you to know the warning signs, so you can get help quickly if something changes. Always speak with your clinician if you're concerned about side effects or any medications you're taking currently.

Who This Helps

This is for anyone taking a GLP-1, whether it's a brand-name drug or a compounded one. You'll also want to read this if you have diabetes, sleep apnea or high blood pressure, since those already raise the risk of NAION on their own.

What did the FDA actually do?

The FDA is requiring the makers of all GLP-1 drugs to add NAION to the warnings section of their labels. It applies to every drug in the class. The FDA calls it a "potential increased risk" and hasn't said the drugs are proven to cause it (FDA).

As of November 10, the FDA's label database didn't show the new warning yet (Healthline). Regulators in Europe and the UK had already added similar warnings, mostly for semaglutide, the drug in Ozempic and Wegovy.

How rare is it?

The FDA calls the risk rare. When it combined 126 clinical trials, it found only 15 cases of NAION in total: 10 in people taking a GLP-1 and 5 in people taking a placebo (FDA).

Put another way, there were about 6.4 cases for every 100,000 years of GLP-1 use, compared with 3.8 for people on a placebo or other diabetes drugs. In adults over 50, NAION already happens in about 2 to 10 of every 100,000 people each year, even without these drugs. People with diabetes start out with a higher risk than that.

Find a provider in your state

Answer a few questions and see live pricing from the providers that ship where you live.

Get started

Do GLP-1s cause it?

Nobody knows yet. The FDA also looked at real-world health records from adults with type 2 diabetes. When it compared GLP-1s with one group of diabetes drugs, it didn't find a clear increase. When it compared them with another group, it did (FDA). The FDA said animal studies didn't show how the drugs could cause it.

Part of the problem is that people who take GLP-1s often already have NAION risk factors, like diabetes, sleep apnea and high blood pressure. That makes it hard to tell what's coming from the drug and what's coming from the health conditions behind it (Cleveland Clinic).

Experts don't agree yet. In a 2026 conference presentation, researchers looked at more than a million military health records and found no higher risk with semaglutide in people with overweight or obesity. That work hasn't been published in a journal yet (Healio).

On the other side, Dr. Joseph Rizzo of Mass Eye and Ear, who co-wrote the 2024 study that raised the concern, told CBS he believes the drugs do raise the risk. Even so, CBS reports he doesn't discourage patients from taking them. "The medicines have really been profoundly beneficial to a large number of people," he said (CBS News). Novo Nordisk told CBS the data don't establish that the drugs cause NAION.

What does NAION feel like?

NAION usually causes sudden, painless vision loss in one eye. Many people first notice it when they wake up. You might see a blurry or missing patch, often in the lower half of your vision, or colors that look dull (Cleveland Clinic).

The hard part is that the vision loss usually lasts, and there's no treatment that brings it back (American Academy of Ophthalmology). Some people also get it in the other eye later.

What should you do?

Start by knowing the signs. If you notice sudden vision loss in one eye, contact your health care provider right away (FDA). Cleveland Clinic calls any sudden vision loss an emergency that needs medical care right away, since it can also be a sign of other serious problems, like a stroke.

If it happens, don't stop your medication on your own. The FDA told Healthline that people with these symptoms should call their provider and not stop their medicine without talking to them first. It also said the benefits of these drugs continue to outweigh the risks when they're used as directed (Healthline).

If you've had NAION before, tell your prescriber. The FDA says the risk of it happening again is higher, and you'll want to talk about whether to keep taking your medication.

You can also ask about an eye exam. The American Optometric Association began recommending an exam of the optic nerve for anyone starting a GLP-1 in 2025 (Review of Optometry).

What if you take a compounded GLP-1?

Compounded medications aren't FDA-approved, and the FDA doesn't check them before they're sold (FDA). The FDA's notice doesn't say whether compounded products will carry this new warning, so you may not see it on your vial. The symptoms to watch for are the same, so ask your prescriber or pharmacy for the safety information that comes with your medication.

Final Takeaway

The FDA is adding a warning about NAION, a rare eye condition, to every GLP-1 medication. It isn't proven that the drugs cause it, but the vision loss can be lasting. Learn the signs: sudden, painless vision loss in one eye, often noticed when you wake up. If it happens, call your provider right away, and don't stop your medication without talking to them first.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

Frequently Asked Questions

Should I stop taking Ozempic because of the vision warning?

The FDA hasn't said to stop, and it told Healthline the benefits still outweigh the risks when the drugs are used as directed. Talk to your prescriber before making any change. If you notice sudden vision loss in one eye, contact your provider right away.

What are the symptoms of NAION?

The most common sign is sudden, painless vision loss in one eye, often noticed on waking. You might also see blurry or missing areas, or colors that look duller than usual.

How common is NAION on GLP-1s?

It's rare. In the FDA's review of 126 trials, there were about 6.4 cases for every 100,000 years of GLP-1 use, compared with 3.8 on a placebo or other diabetes drugs.

Does this warning apply to compounded semaglutide or tirzepatide?

The FDA's notice doesn't mention compounded drugs. Ask your pharmacy whether any warning comes with yours. The symptoms to watch for are the same either way.

Is the vision loss from NAION permanent?

Usually, yes. Some people improve a little, but there's no treatment that restores the lost vision. So if you notice symptoms, get checked quickly.

FDA Adds a Vision-Loss Warning to Every GLP-1. What It Means for You